{"entity":{"id":"nct07321847","kind":"trial","name":"Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases","aka":["INJECTABL-3"],"tldr":"A phase 2/3 trial in colorectal cancer, run by Immunophotonics, Inc., not yet recruiting.","summary":"Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases is a phase 2/3, randomised interventional study registered as NCT07321847 by Immunophotonics, Inc., with a registry enrolment figure of 717 participants, started 2026-05 and due to reach its primary completion in 2033-12. Interventions recorded: 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water; 1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water.; Microwave (thermal) tumor ablation. Conditions listed: Colorectal Cancer (CRC); Colon Cancer Liver Metastases; Rectal Cancer; Rectal Cancer With Liver Metastases; Colorectal Liver Metastasis (CRLM). Primary outcome: To compare the efficacy of IP-001 following standard-of-care (SOC) complete hepatic tumor ablation vs SOC complete hepatic tumor ablation alone in prolonging progression-free survival. Colorectal eligibility wording from the registry: \"No residual primary colorectal tumor at Treatment Day 1 or plans to have the primary tumor excised within 4-12 weeks following Treatment Day 1\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07321847","url":"https://clinicaltrials.gov/study/NCT07321847"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["thermal-ablation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07321847","phase":"2/3","setting":"Intratumoral Injection of IP-001 Following Standard-of-care Complete Hepatic Tumor Ablation in Patients With Liver-only Metastatic Colorectal Cancer","sponsor":"Immunophotonics, Inc.","enrolled":717,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07321847/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}